Affiliation:
1. From the University of California at Los Angeles (UCLA) Stroke Center (C.S.K., S.S., J.L.S.), Department of Neurology (C.S.K., S.S., J.L.S.), and Department of Emergency Medicine (S.S.), UCLA Medical Center; and Comprehensive Stroke Center and Department of Neurology, University of Pennsylvania, Philadelphia (D.S.L.).
Abstract
Background and Purpose
—The advent of controlled clinical trials revolutionized clinical medicine over the course of the 20th century. The objective of this study was to quantitatively characterize developments in clinical trial methodology over time in the field of acute ischemic stroke.
Methods
—All controlled trials targeting acute ischemic stroke with a final report in English were identified through MEDLINE and international trial registries. Data regarding trial design, implementation, and results were extracted. A formal 100-point scale was used to rate trial quality.
Results
—A total of 178 controlled acute stroke trials were identified, encompassing 73 949 patients. Eighty-eight trials involved neuroprotective agents, 59 rheological/antithrombotic agents, 26 agents with both neuroprotective and rheological/antithrombotic effects, and 5 a nonpharmacological intervention. Only 3 trials met conventional criteria for a positive outcome. Between the 1950s and 1990s, the number of trials per decade increased from 3 to 99, and mean trial sample size increased from 38 (median, 26) to 661 (median, 113). During 1980–1999, median time window allowed for enrollment decreased per half decade from 48 to 12 hours. Reported pharmaceutical sponsorship increased substantially over time, from 38% before 1970 to 68% in the 1990s. Trial quality improved substantially from a median score of 12 in the 1950s to 72 in the 1990s.
Conclusions
—Accelerating trends in acute stroke controlled trials include growth in number, sample size, and quality, and reduction in entry time window. These changes reflect an increased understanding of the pathophysiology of acute stroke, the imperative for treatment initiation within a critical time window, and more sophisticated trial design.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Advanced and Specialised Nursing,Cardiology and Cardiovascular Medicine,Clinical Neurology
Reference45 articles.
1. Brass LM Alter M. Clinical trial design for cerebrovascular disorders. In: Fisher M ed. Stroke Therapy . Boston Mass: Butterworth-Heinemann; 1995:135–170.
2. Daniel 1:11–21.
3. Bulpitt CJ. Randomised Controlled Clinical Trials . 2nd ed. Boston Mass: Kluwer Academic Publishers; 1996.
4. Tissue Plasminogen Activator for Acute Ischemic Stroke
5. Cochrane Stroke Group CRG. The Cochrane Library issue 4 1999. Oxford UK: Update Software.
Cited by
206 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献